Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis Ketek July Launch Will Highlight Targeted Antibacterial Activity

Executive Summary

Aventis' promotional message for Ketek will center on the antibiotic's ability to specifically target all pathogens commonly associated with respiratory tract infections without affecting other bacterial strains

You may also be interested in...



UnitedHealth Rx Registry Will Test Four Highest Prescribed NMEs In 2004

UnitedHealth is testing its new postmarketing surveillance drug database on the four most frequently prescribed new molecular entities launched in 2004

UnitedHealth Rx Registry Will Test Four Highest Prescribed NMEs In 2004

UnitedHealth is testing its new postmarketing surveillance drug database on the four most frequently prescribed new molecular entities launched in 2004

Ketek, Allegra Deserve Special Formulary Status – Aventis Consultants

The ketolide drug class should be added to the U.S. Pharmacopeia's model drug classification system as a unique pharmacologic class, Stephen Jenkins, PhD, Carolinas Medical Center said during an Aug. 27 public meeting on the proposed Medicare Rx formulary guidelines

Related Content

UsernamePublicRestriction

Register

PS043652

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel